The combined effects of celecoxib and minocycline hydrochloride on inhibiting the osseous metastasis of breast cancer in nude mice

Cancer Biotherapy and Radiopharmaceuticals

Volumn 23, Issue 4, 2008, Pages 469-476

  Niu, Guangfeng ^a   Liao, Zhichao ^a   Cai, Lin ^a   Wei, Renxiong ^a   Sun, Li ^b  

^a WUHAN UNIVERSITY   (China)

^b Binzhou Central Hospital   (China)

Author keywords

Alkaline phosphatase; Breast cancer; Celecoxib; Minocycline chloride; Osseous metastasis

Indexed keywords

CELECOXIB; GELATINASE B; MINOCYCLINE; TETRACYCLINE; VASCULOTROPIN;

ALKALINE PHOSPHATASE BLOOD LEVEL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; BONE METASTASIS; BREAST CANCER; CANCER CELL CULTURE; CANCER INHIBITION; CELL DEATH; CELL DENSITY; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DRUG EFFECT; FEMALE; MICROVASCULATURE; MONOTHERAPY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR VOLUME;

ALKALINE PHOSPHATASE; ANIMALS; APOPTOSIS; BODY WEIGHT; BONE NEOPLASMS; BREAST NEOPLASMS; CELL LINE, TUMOR; CYCLOOXYGENASE INHIBITORS; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; MATRIX METALLOPROTEINASE 9; MICE; MICE, INBRED STRAINS; MICE, NUDE; MINOCYCLINE; PYRAZOLES; SULFONAMIDES; TUMOR BURDEN; VASCULAR ENDOTHELIAL GROWTH FACTOR A; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 51349109618     PISSN: 10849785     EISSN: None     Source Type: Journal    
DOI: 10.1089/cbr.2008.0475     Document Type: Article

References (29)

1. Diel IJ. Prognostic factors for skeletal relapse in breast cancer. Cancer Treat Rev 2001;27:153.
2. Galasko CSB. Skeletal Metastasis. London: Butterworth, 1986.
3. Duivenvoorden WC, Hirte HW, Singh G. Use of tetracycline as an inhibitor of matrix metalloproteinase activity secreted by human bone-metastasizing cancer cells. Invasion Metast 1997;17:312.
4. Vallee BL, Auld DS. Zinc coordination, function, and structure of zinc enymes and other proteins. Biochemistry 1990;29:5647.
5. Rifkin BR, Vernillo AT, Golub LM. Blocking periodontal disease progression by inhibiting tissue-destructive enzymes: A potential therapeutic role for tetracyclines and their chemically modified analogs. J Periodontol 1993;64(Suppl 8):819.
6. Lanza-Jacoby S, Miller S, Flynn J, et al. The cyclo-oxygenase-2 inhibitor, celecoxib, prevents the development of mammary tumors in Her-2/neu mice. Cancer Epidemiol Biomark Prev 2003;12:1486.
7. Alshafie G, Abou-Issa HM, Seibert K, et al. Chemotherapeutic evaluation of celecoxib, a cyclo-oxygenase-2 (COX-2) inhibitor, in a rat mammary tumor model. Proc Am Assn Cancer Res 2000;41:3144A.
8. Harms JF, Welch DR. MDA-MB-435 human breast carcinoma metastasis to bone. Clin Exp Metast 2003;20:327.
9. Wei H, Wang HF, Hartmann LC, et al. In vivo quantitation of rare circulating tumor cells by multiphoton intravital flow cytometry. PNAS 2007;28:11760.
10. Parker SL, Tong T, Bolden S, et al. Cancer statistics, 1997. CA-A Cancer J Clin 1997;47:5.
11. Statistics Department of Germany. Statistical Yearbook of Germany 1995 [Public Health]. Stuttgart: Metzler-Poeschel, 1995.
12. Masferrer JL, Leahy KM, Koki AT, et al. Antiangiogenic and antitumor activities of cyclo-oxygenase-2 inhibitors. Cancer Res 2000;5:1306.
13. Taketo MM. Cyclo-oxygenase-2 inhibitors in tumorigenesis (Part II). J Natl Cancer Inst 1998;21:1609.
14. Howe LR, Subbaramaiah K, Brown AM, et al. Cyclooxygenase-2: A target for the prevention and treatment of breast cancer. Endocr Relat Cancer 2001;8:97.
15. Giercksky KE. COX-2 inhibition and prevention of cancer. Best Pract Res Clin Gastroenterol 2001;15:821.
16. Arun B, Goss P. The role of COX-2 inhibition in breast cancer treatment and prevention. Semin Oncol 2004;31(Suppl 7)2:22.
17. Liao Z, Milas L, Komaki R, et al. Combination of a COX-2 inhibitor with radiotherapy or radiochemotherapy in the treatment of thoracic cancer. Am J Clin Oncol 2003;26:S85.
18. Irie T, Tsujii M, Tsuji S, et al. Synergistic antitumor effects of celecoxib with 5-fluorouracil depend on IFNgamma. Int J Cancer 2007;121:878.
19. Pan YY, Xu SP, Jia XY, et al. Combination of cyclooxygenase-2 inhibitor and doxorubicin increases the growth inhibition and apoptosis in human hepatocellular carcinoma cells. Exp Oncol 2007;29:23.
20. Sapadin AN, Fleischmajer R. Tetracyclines: Nonantibiotic properties and their clinical implications. J Am Acad Dermatol 2006;54:258.
21. Weingart JD, Sipos EP, Brem H. The role of minocycline in the treatment of intracranial 9L glioma. J Neurosurg 1995;82:635.
22. 2 concentrations in nipple aspirate fluid from high-risk postmenopausal women and women with breast cancer. BMC Cancer 2006;6:248.
23. Itoh T, Tanioka M, Yoshida H, et al. Reduced angiogenesis and tumor progression in gelatinase A-deficient mice. Cancer Res 1998;58:1048.
24. Coussens LM, Tinkle CL, Hanahan D, et al. MMP-9 supplied by bone-marrow-derived cells contributes to skin carcinogenesis. Cell 2000;103:481.
25. Hiratsuka S, Nakamura K, Iwai S, et al. MMP-9 induction by vascular endothelial growth factor receptor-1 is involved in lung-specific metastasis. Cancer Cell 2002;2:289.
26. Kanakis I, Nikolaou M, Pectaside D, et al. Determination and biological relevance of serum cross-linked type I collagen N-telopeptide and bone-specific alkaline phosphatase in breast metastatic cancer. J Pharmaceut Biomed Anal 2004;34:827.
27. Bundred NJ, Barnes NLP. Potential use of COX-2-aromatase inhibitor combinations in breast cancer. Br J Cancer 2005;93(Suppl 1):S10.
28. Plate KH, Breier G, Weich HA, et al. Vascular endothelial growth factor is a potential tumour angiogenesis factor in human gliomas in vivo. Nature 1992;359:845.
29. Hao L, Zhang CH, Qiu YH, et al. Recombination of CXCR4, VEGF, and MMP-9 predicting lymph node metastasis in human breast cancer. Cancer Lett 2007;253:34.